Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      ShangPharma Announces Fourth Quarter and Fiscal Year 2010 Results


      News provided by

      ShangPharma Corporation

      Mar 15, 2011, 06:00 ET

      Share this article

      Share this article


      SHANGHAI, March 15, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its financial results for its fourth quarter and the fiscal year ended December 31, 2010.

      To help management and investors gain a better understanding of ShangPharma's operating performance, the Company presents certain non-GAAP measures, each of which excludes IPO bonuses and expenses relating to or the effect of share-based compensation. See "About Non-GAAP Financial Measures" and "Reconciliation of GAAP to Non-GAAP Financial Data" below for more information about the non-GAAP financial measures included in this press release.

      Fourth Quarter 2010 Highlights

      • Net revenues increased by 29.4% year-over-year to $25.6 million, driven by a 17.5% increase in full-time-equivalent ("FTE") services and a 67.9% increase in fee-for-service-based services.
      • GAAP gross profit increased by 28.1% year-over-year to $8.3 million. GAAP gross margin was 32.3%, down from 32.6% in the fourth quarter of 2009.
      • Non-GAAP gross profit increased by 35.3% year-over-year to $8.8 million. Non-GAAP gross margin was 34.4%, up from 32.9% in the fourth quarter of 2009.
      • GAAP profit from operations decreased 65.7% year-over-year to $0.9 million, primarily due to higher share-based compensation expenses. GAAP operating margin was 3.6%, down from 13.5% in the fourth quarter of 2009.
      • Non-GAAP profit from operations increased by 54.2% year-over-year to $4.3 million. Non-GAAP operating margin was 16.7%, up from 14.0% in the fourth quarter of 2009.
      • GAAP net income slightly increased 1.3% year-over-year to $2.5 million. GAAP diluted earnings per ADS were $0.14, compared to $0.16 in the fourth quarter of 2009, primarily due to higher share-based compensation expenses.
      • Non-GAAP net income increased by 126.2% year-over-year to $5.9 million.  Non-GAAP diluted earnings per ADS were $0.32, compared to $0.17 in the fourth quarter of 2009.

      Full Year 2010 Highlights

      • Net revenues increased by 24.9% year-over-year to $90.3 million, supported by a 15.5% increase in FTE services and 59.0% rise in fee-for-service-based services.
      • Average revenue per customer for the top-10 customers increased to $5.7 million, compared with $4.7 million in 2009.
      • Total number of customers leapt to 237, up from 134 in 2009.
      • GAAP gross profit increased by 26.2% year-over-year to $30.1 million. GAAP gross margin was 33.4%, up from 33.0% in 2009.
      • Non-GAAP gross profit increased by 29.5% year-over-year to $31.1 million. Non-GAAP gross margin was 34.5%, up from 33.2% in 2009.
      • GAAP profit from operations increased by 1.4% year-over-year to $10.4 million. GAAP operating margin was 11.5%, down from 14.2% in 2009, primarily due to higher share-based compensation expenses.
      • Non-GAAP profit from operations increased by 36.9% year-over-year to $14.4 million. Non-GAAP operating margin was 15.9%, up from 14.5% in 2009.
      • GAAP net income increased by 32.6% year-over-year to $13.0 million. GAAP diluted earnings per ADS were $0.78, compared to $0.63 in 2009.
      • Non-GAAP net income increased by 68.9% year-over-year to $17.0 million. Non-GAAP diluted earnings per ADS were $1.07, compared to $0.65 in 2009.

      Management Comment

      Michael Xin Hui, founder and Chief Executive Officer of ShangPharma, commented, "We are pleased to report solid results for the fourth quarter and fiscal year 2010. All of our businesses contributed to the strong results, which saw growth accelerate from the prior year. Our continued efforts to expand our spectrum of services resulted in a significant increase in our customer base and greater spending levels from our top-10 customers. We continue to invest in new state-of-the art manufacturing facilities and recently completed the construction of the first phase of our new c-GMP-quality multi-purpose facility in Fengxian, which focuses on pharmaceutical development services. We also made good progress on biologics services as we signed a major deal with a leading global pharmaceutical company.  In addition, we expect our enhanced platform of integrated services to support our overall revenue growth and margin expansion in the future.  

      It is well known that the global pharmaceutical industry is facing numerous challenges which have caused many companies to reevaluate their R&D strategies and internal programs. Going forward, we remain optimistic about the CRO industry in China as it possesses a combination of high quality and low cost solutions for pharmaceutical R&D. ShangPharma is well-positioned to capitalize on this trend given our talented team of scientists, our focus on exceptional quality and our broad range of services that we continue to expand in response to market dynamics.  Our 2010 results illustrate the growing demand for our offerings among the leading companies in the world.  We expect this to continue in 2011 and beyond."

      William Dai, Chief Financial Officer, added, "We achieved excellent profit growth for the quarter and the year just completed due to an acceleration in sequential revenue growth and our continued focus on improving operational efficiency.  Our internal efforts to drive significant margin expansion on a non-GAAP basis helped mitigate the continued appreciation of the Renminbi and wage inflation.  In 2011, we expect to continue to benefit from our efficiency programs to offset these rising costs and preserve margins."

      Fourth Quarter 2010 Results

      Net revenues were $25.6 million, an increase of 29.4% from $19.8 million in the fourth quarter of 2009, primarily due to a larger customer base, higher business volumes from the Company's top customers, expanded service offering, higher average FTE rates and a favorable shift in the service mix.  

      Net revenues from full-time-equivalent ("FTE")-based services were $17.8 million, an increase of 17.5% from $15.1 million in the fourth quarter of 2009, primarily due to an increase in FTE numbers and higher FTE rates.

      Net revenues from fee-for-service-based services were $7.8 million, an increase of 67.9% from $4.7 million in the fourth quarter of 2009, primarily driven by the Company's newer service offerings including discovery biology, preclinical development and pharmaceutical development services.  The majority of these newer offerings are fee-for-service-based.  The higher growth in fee-for-service-based revenues reflects the Company's ability to cross-sell newer services to existing customers as well as strong demand from new customers.

      Gross profit was $8.3 million, an increase of 28.1% from $6.5 million in the fourth quarter of 2009, primarily due to the increase in revenues, favorable service mix, operational efficiency improvement and efficient material usage.  The increase was partially offset by the continued appreciation of the Renminbi and higher share-based compensation expenses.

      Non-GAAP gross profit was $8.8 million, an increase of 35.3% from $6.5 million in the fourth quarter of 2009, primarily due to the increase in revenues, favorable service mix, operational efficiency improvement and efficient material usage.  The increase was partially offset by the continued appreciation of the Renminbi.

      Gross margin decreased slightly to 32.3% from 32.6% in the fourth quarter of 2009.  The favorable service mix, operational efficiency improvement and efficient material usage were primarily offset by continued Renminbi appreciation and higher share-based compensation expenses.  

      Non-GAAP gross margin increased to 34.4% from 32.9% in the fourth quarter of 2009, primarily due to the favorable service mix, operational efficiency improvement and efficient material usage.  The rise was partially offset by continued Renminbi appreciation.

      Operating expenses (selling, marketing, general and administrative) were $7.3 million, an increase of 94.5% from $3.8 million in the fourth quarter of 2009, primarily due to higher share-based compensation expenses including the one-time restricted share unit ("RSU") costs of approximately $2.2 million that were incurred upon completion of the Company's initial public offering and a build-up of corporate managerial, sales and supporting infrastructure.  

      Non-GAAP operating expenses were $4.6 million, an increase of 21.3% from $3.8 million in the fourth quarter of 2009, primarily due to a build-up of corporate managerial, sales and supporting infrastructure.

      Profit from operations was $0.9 million, a decrease of 65.7% from $2.7 million in the fourth quarter of 2009, primarily due to higher share-based compensation expenses and a continuous build-up of corporate managerial, sales and supporting infrastructure.  The decline was partially offset by the increase in gross profit.  

      Non-GAAP profit from operations was $4.3 million, an increase of 54.2% from $2.8 million in the fourth quarter of 2009, primarily due to higher gross profit and better cost control over selling, general and administrative expenses.

      Operating margin declined to 3.6% from 13.5% in the fourth quarter of 2009.  The favorable service mix, operational efficiency improvement and efficient material usage were offset by higher share-based compensation expenses and continued Renminbi appreciation.

      Non-GAAP operating margin increased to 16.7% from 14.0% in the fourth quarter of 2009, primarily due to favorable service mix, operational efficiency improvement and efficient material usage.  The rise was partially offset by continued Renminbi appreciation.  

      Net income slightly increased 1.3% year-over-year to $2.5 million.  The lower profit from operations was offset by higher other income, including a mark-to-market gain on foreign exchange forward contracts, income from government grants and investment income.  

      Non-GAAP net income was $5.9 million, an increase of 126.2% from $2.6 million in the fourth quarter of 2009, primarily due to higher profit from operations and higher other income.  

      Diluted earnings per ADS were $0.14, a decrease of 12.5% from $0.16 in the fourth quarter of 2009.  

      Non-GAAP diluted earnings per ADS were $0.32, an increase of 88.2% from $0.17 in the fourth quarter of 2009.

      Fiscal Year 2010 Results

      Net revenues were $90.3 million, an increase of 24.9% from $72.3 million in 2009, primarily due to a larger customer base, higher business volumes from the Company's top customers, expanded service offering, higher average FTE rates and a favorable shift in the service mix.  

      Net revenues from FTE-based services were $65.4 million, an increase of 15.5% from $56.6 million in 2009, primarily due to higher FTE numbers and higher FTE rates.  

      Net revenues from fee-for-service-based services were $24.9 million, an increase of 59.0% from $15.7 million in 2009, primarily due to rapid growth from newer offerings, including discovery biology, preclinical development and pharmaceutical development services, most of which are fee-for-service-based projects.  

      Gross profit was $30.1 million, an increase of 26.2% from $23.9 million in 2009.  The improvement primarily resulted from the increase in revenues, favorable service mix, efficient material usage and operational efficiency improvement, and was partially offset by continued appreciation of the Renminbi and higher share-based compensation expenses.

      Non-GAAP gross profit was $31.1 million, an increase of 29.5% from $24.0 million in 2009, primarily due to the increase in revenues, favorable service mix, efficient material usage and operational efficiency improvement.  The increase was partially offset by continued appreciation of the Renminbi.    

      Gross margin increased to 33.4% from 33.0% in 2009, primarily due to the favorable service mix, efficient material usage and operational efficiency improvement.  The increase was partially offset by continued appreciation of the Renminbi and higher share-based compensation expenses.  

      Non-GAAP gross margin increased to 34.5% from 33.2% in 2009, primarily due to the favorable service mix, efficient material usage and operational efficiency improvement.  The rise was partially offset by continued appreciation of the Renminbi.

      Operating expenses (selling, marketing, general and administrative) were $19.7 million, an increase of 45.0% from $13.6 million in 2009, primarily due to higher share-based compensation including the one-time RSU costs of approximately $2.2 million that were incurred upon completion of the Company's initial public offering and a build-up of corporate managerial, sales and supporting infrastructure.  

      Non-GAAP operating expenses were $16.7 million, an increase of 23.7% from $13.5 million in 2009, primarily due to a continuing build-up of corporate managerial, sales and supporting infrastructure.  

      Profit from operations was $10.4 million, an increase of 1.4% from $10.2 million in 2009.  The higher gross profit was offset by the increase of share-based compensation expenses and a build-up of corporate managerial, sales and supporting infrastructure.  

      Non-GAAP profit from operations was $14.4 million, an increase of 36.9% from $10.5 million in 2009, primarily due to higher gross profits and better cost control over selling, general and administrative expenses.

      Operating margin declined to 11.5% from 14.2% in 2009.  The favorable service mix, efficient material usage and operational efficiency improvement were offset by higher share-based compensation and continued appreciation of the Renminbi.

      Non-GAAP operating margin increased to 15.9% from 14.5% in 2009, primarily due to the favorable service mix, efficient material usage and operational efficiency improvement.  The rise was partially offset by the continued appreciation of the Renminbi.  

      Net income was $13.0 million, an increase of 32.6% from $9.8 million in 2009.  The lower profit from operations was offset by higher other income, including a mark-to-market gain on foreign exchange forward contracts and income from government grants.

      Non-GAAP net income was $17.0 million, an increase of 68.9% from $10.1 million in 2009, primarily due to higher profit from operations and higher other income.  

      Diluted earnings per ADS were $0.78, an increase of 23.8% from $0.63 in 2009.  

      Non-GAAP diluted earnings per ADS were $1.07, an increase of 64.6% from $0.65 in 2009.

      Financial Position  

      As of December 31, 2010, the Company had cash and cash equivalents of $49.2 million and short term debt of $0.8 million.  The cash balance included $44.3 million in net proceeds from the Company's initial public offering in October 2010.  

      Full Year 2011 Guidance

      For the full year 2011, the Company expects:

      • Net revenues to be approximately $111.1 – $115.6 million, which represents growth of approximately 23.0% – 28.0% compared with full year 2010.  
      • Non-GAAP gross margin to be approximately 33.5% – 35.5%, which is within the same range as non-GAAP gross margin of 34.5% in 2010.
      • Capital expenditure to be $28 - $32 million, including $6 million rolling payment lag impact carried forward from 2010.

      This reflects the Company's current view and is subject to change.

      Conference Call

      ShangPharma will host a conference call and live webcast at 8 am Eastern Daylight Time (EDT) on March 15, 2011 (8 pm Beijing time on March 15, 2011).

      The dial-in details for the live conference call are as follows:

      - U.S. Toll Free Number:

      1 800 299 9630

      - International Dial-in Number:

      1 617 786 2904

      - Mainland China Toll Free Numbers:              

      10 800 152 1490 (North)


      10 800 852 1490 (South)

      - Hong Kong Toll Free Number:

      800 963 844

           Conference ID: SHP




      A live and archived webcast of the conference call will be available on the Investor Relations section of ShangPharma's website at www.shangpharma.com

      A telephone replay of the call will be available for seven days, beginning two hours after the conclusion of the conference call from March 15, 2011 to March 22, 2011.

      The dial-in details for the replay are as follows:

      - U.S. Toll Free Number:

      1 888 286 8010

      - International Dial-in Number:                          

      1 617 801 6888

           Conference ID: 85666096




      ABOUT SHANGPHARMA CORPORATION

      ShangPharma Corporation (NYSE: SHP) is a leading China-based contract research organization providing high quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.

      Safe Harbor: Forward-Looking Statements

      This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "likely to" or other similar expressions. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. Among other things, the section titled "Full Year 2011 Guidance" and quotations from management in this press release, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its reports filed or furnished with the U.S. Securities and Exchange Commission, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements and are subject to change, and such change may be material and may have a material adverse effect on the Company's financial condition and results of operations for one or more periods. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained, either expressly or impliedly, in any of the forward-looking statements in this press release. The Company expects to face potential risks and uncertainties related to its ability to, among other things, attract, train, motivate and retain skilled scientists; diversify its customer base and adapt to potential loss of sales to, or significant reduction in orders from, any of its major customers; adapt its business to industry trends, such as fluctuations in the R&D budgets of pharmaceutical and biotechnology industry participants; protect the intellectual property rights of its customers; comply with applicable regulations and industry standards; compete effectively in its industry, which may subject it to increasing pricing pressure and reduce the demand for its services; expand and market its services and manage its growth; and develop and maintain effective internal control over financial reporting; as well as other risks outlined in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and the Company does not undertake any obligation to update any such information, except as required under applicable law.

      About Non-GAAP Financial Measures

      To supplement the Company's consolidated financial results presented in accordance with United States Generally Accepted Accounting Principles ("GAAP"), the Company uses the following non-GAAP financial measures: (1) gross profit, (2) gross margin, (3) profit from operations, (4) operating expenses, (5) operating margin, (6) net income, and (7) diluted earning per ADS, each of which excludes IPO bonuses and expenses relating to or the effect of share-based compensation. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. For more information on these non-GAAP financial measures, please see the table captioned "Reconciliation of GAAP and non-GAAP Financial Data" set forth at the end of this press release.

      The Company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its operating performance by excluding expenses relating to or the effect of share-based compensation and IPO bonuses that may not be indicative of its operating performance. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its operating performance and when planning and forecasting future periods. These non-GAAP financial measures also facilitate management's internal comparisons to the Company's historical performance. The Company computes its non-GAAP financial measures using the same consistent method from quarter to quarter. The Company believes these non-GAAP financial measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and operational decision making. A limitation of using non-GAAP financial measures excluding expenses relating to or the effect of share-based compensation is that these expenses and effects have been and will continue to be significant recurring expenses in the Company's business for the foreseeable future. Management compensates for these limitations by providing specific information regarding the GAAP amount excluded from each non-GAAP measure. The accompanying tables have more details on the reconciliation between non-GAAP financial measures and their most comparable GAAP financial measures.

      For further information, please contact:


      ShangPharma Corporation

      In Shanghai, China

      Lan Xie

      VP of Finance and Operations

      E-mail: [email protected]


      Christensen

      In New York, US

      Kimberly Minarovich, +1 917-533-3268

      [email protected]


      In Hong Kong

      Tip Fleming, +852-9212-0684

      [email protected]



      SHANGPHARMA CORPORATION

      UNAUDITED CONSOLIDATED BALANCE SHEET

      (in thousands of U.S. dollars, except for ordinary share data)



      December 31,

      December 31,


      2009

      2010




      ASSETS



      Current assets:



       Cash

      12,238

      49,160

       Restricted cash

      146

      688

       Investment in securities

      417

      -

       Accounts receivable, net

      14,292

      16,908

       Inventories

      1,145

      1,259

       Prepayments and other current assets

      1,454

      4,983

       Deferred tax assets

      374

      315

      Total current assets

      30,066

      73,313

      Non-current assets:



       Property, equipment and software, net

      35,725

      60,147

       Land use right, net

      4,178

      4,221

       Derivative assets

      -

      261

      Total non-current assets

      39,903

      64,629

      Total assets

      69,969

      137,942




      LIABILITIES



      Current liabilities:



       Short-term bank borrowings

      -

      755

       Accounts payable

      4,717

      10,549

       Amounts due to related parties

      1,787

      1,025

       Salary and welfare payable

      2,991

      4,040

       Income tax payable

      1,589

      1,910

       Advance from customers

      392

      1,650

       Other payables and accruals

      4,014

      4,477

      Total current liabilities

      15,490

      24,406

      Total liabilities

      15,490

      24,406

      Commitments and contingencies






      Series A convertible preferred shares (US$0.001 par value;
      70,000,650 shares authorized; 69,994,014 and none issued and
      outstanding as of December 31, 2009 and 2010, respectively

      34,356

      -

      EQUITY



      Ordinary shares (US$0.001 par value; 429,999,350 shares authorized;
      208,005,986 and 335,600,000 shares issued and outstanding as of
      December 31, 2009 and 2010, respectively)

      208

      336

      Additional paid in capital

      321

      78,989

      Statutory reserves

      5,446

      6,771

      Retained earnings

      12,008

      23,680

      Accumulated other comprehensive income

      2,140

      3,760

      Total equity

      20,123

      113,536

      Total liabilities and equity

      69,969

      137,942



      SHANGPHARMA CORPORATION

      UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

      (in thousands of U.S. dollars, except for ADS(1) data and per ADS data)



      Three months ended

      Twelve months ended


      December 31,

      December 31,


      2009

      2010

      % Change

      2009

      2010

      % Change








      Net revenue

      19,796

      25,609

      29.4%

      72,285

      90,281

      24.9%

      Cost of revenue

      (13,344)

      (17,345)

      30.0%

      (48,433)

      (60,168)

      24.2%

      Gross profit

      6,452

      8,264

      28.1%

      23,852

      30,113

      26.2%








      Operating expenses







          Selling and marketing

      (539)

      (703)

      30.4%

      (1,609)

      (2,293)

      42.5%

          General and administrative

      (3,239)

      (6,645)

      105.2%

      (11,994)

      (17,429)

      45.3%

      Total operating expenses

      (3,778)

      (7,348)

      94.5%

      (13,603)

      (19,722)

      45.0%

      Profit from operations

      2,674

      916

      -65.7%

      10,249

      10,391

      1.4%








      Other income (expenses), net:

      246

      2,263

      819.9%

      1,102

      4,691

      325.7%

      Income from operations before income
      taxes

      2,920

      3,179

      8.9%

      11,351

      15,082

      32.9%








      Income taxes

      (406)

      (633)

      55.9%

      (1,552)

      (2,085)

      34.3%

      Net income attributable to ShangPharma Corporation

      2,514

      2,546

      1.3%

      9,799

      12,997

      32.6%








      Allocation to preferred shareholders

      (633)

      (108)

      -82.9%

      (2,467)

      (2,739)

      11.0%

      Net income attributable to ShangPharma Corporation's ordinary
      shareholders

      1,881

      2,438

      29.6%

      7,332

      10,258

      39.9%








      Net income attributable to ShangPharma Corporation's ordinary
      shareholders per ADS







          Basic

      0.16

      0.14

      -12.5%

      0.63

      0.79

      25.4%

          Diluted

      0.16

      0.14

      -12.5%

      0.63

      0.78

      23.8%








      Weighted average ADS outstanding







          Basic

      11,555,888

      17,257,553


      11,555,888

      12,993,020


          Diluted

      11,567,288

      17,563,304


      11,558,738

      13,222,233









      Note: The unaudited diluted earning per ADS has excluded the effect of allocation to preferred shareholders in both net income and weighted average ADS outstanding.

      (1) Each ADS represents 18 ordinary shares.



      SHANGPHARMA CORPORATION

      RECONCILIATION OF GAAP TO NON-GAAP FINANACIAL DATA

      (in thousands of U.S. dollars, except for ADS(2) data and per ADS data)



      Three months ended

      Twelve months ended


      December 31,

      December 31,


      2009

      2010

      %

      2009

      2010

      %

      GAAP gross profit

      6,452

      8,264

      28.1%

      23,852

      30,113

      26.2%

      GAAP gross margin

      32.6%

      32.3%


      33.0%

      33.4%


      Adjustments:







         Share-based compensation

      68

      557

      719.1%

      179

      1,003

      460.3%

      Non-GAAP gross profit

      6,520

      8,821

      35.3%

      24,031

      31,116

      29.5%

      Non-GAAP gross margin

      32.9%

      34.4%


      33.2%

      34.5%









      GAAP operating expenses

      (3,778)

      (7,348)

      94.5%

      (13,603)

      (19,722)

      45.0%

      Adjustments:







         IPO bonuses

      -

      235


      -

      235


         Share-based compensation

      27

      2,563

      9392.6%

      73

      2,745

      3660.3%

      Non-GAAP operating expenses

      (3,751)

      (4,550)

      21.3%

      (13,530)

      (16,742)

      23.7%








      GAAP profit from operations

      2,674

      916

      -65.7%

      10,249

      10,391

      1.4%

      GAAP operating margin

      13.5%

      3.6%


      14.2%

      11.5%


      Adjustments:







         IPO bonuses

      -

      235


      -

      235


         Share-based compensation

      95

      3,120

      3184.2%

      252

      3,748

      1387.3%

      Non-GAAP profit from operations

      2,769

      4,271

      54.2%

      10,501

      14,374

      36.9%

      Non-GAAP operating margin

      14.0%

      16.7%


      14.5%

      15.9%









      GAAP net income

      2,514

      2,546

      1.3%

      9,799

      12,997

      32.6%

      GAAP net margin

      12.7%

      9.9%


      13.6%

      14.4%


      Adjustments:







         IPO bonuses

      -

      235


      -

      235


         Share-based compensation

      95

      3,120

      3184.2%

      252

      3,748

      1387.3%

      Non-GAAP net income

      2,609

      5,901

      126.2%

      10,051

      16,980

      68.9%

      Non-GAAP net margin

      13.2%

      23.0%


      13.9%

      18.8%









      GAAP net income attributable to
      ShangPharma Corporation's ordinary
      shareholders per ADS, diluted :

      0.16

      0.14

      -12.5%

      0.63

      0.78

      23.8%

      Adjustments:







         IPO bonuses

      -

      0.01


      -

      0.02


         Share-based compensation

      0.01

      0.17


      0.02

      0.27


      Non-GAAP net income attributable to
      ShangPharma Corporation's ordinary
      shareholders per ADS, diluted:

      0.17

      0.32

      88.2%

      0.65

      1.07

      64.6%








      Weighted average ADS outstanding - basic
      (Non-GAAP)

      11,555,888

      17,257,553


      11,555,888

      12,993,020


      Weighted average ADS outstanding - diluted
      (Non-GAAP)

      11,567,288

      17,563,304


      11,558,738

      13,222,233









      Note: The unaudited diluted earning per ADS has excluded the effect of allocation to preferred shareholders in both net income and weighted average ADS outstanding.

      (2) Each ADS represents 18 ordinary shares



      SOURCE ShangPharma Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.